Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA.

Nat Med. 2007 Jul;13(7):843-50. Epub 2007 Jun 10.

PMID:
17558415
2.

IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform.

Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, Seder RA.

J Exp Med. 2010 Jul 5;207(7):1421-33. doi: 10.1084/jem.20092532. Epub 2010 Jun 7.

3.

Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.

Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, Vogel JC.

Hum Gene Ther. 1998 Sep 1;9(13):1899-907.

PMID:
9741428
4.

Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.

Kronenberg K, Brosch S, Butsch F, Tada Y, Shibagaki N, Udey MC, von Stebut E.

J Invest Dermatol. 2010 Nov;130(11):2602-10. doi: 10.1038/jid.2010.171. Epub 2010 Jun 24.

5.
6.

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P.

Science. 1994 Jan 14;263(5144):235-7.

PMID:
7904381
7.

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP.

Infect Immun. 1995 Nov;63(11):4261-7.

8.

Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.

Cote-Sierra J, Bredan A, Toldos CM, Stijlemans B, Brys L, Cornelis P, Segovia M, de Baetselier P, Revets H.

Infect Immun. 2002 Jan;70(1):240-8.

9.

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.

Vaccine. 2004 May 7;22(15-16):1930-40.

PMID:
15121305
10.

The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major.

Kemp M, Handman E, Kemp K, Ismail A, Mustafa MD, Kordofani AY, Bendtzen K, Kharazmi A, Theander TG.

FEMS Immunol Med Microbiol. 1998 Mar;20(3):209-18.

12.
13.
14.
15.
17.

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.

Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.

J Exp Med. 1997 Oct 6;186(7):1137-47.

19.

IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.

Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM.

J Immunol. 2005 Aug 15;175(4):2517-24.

20.

The immunology of susceptibility and resistance to Leishmania major in mice.

Sacks D, Noben-Trauth N.

Nat Rev Immunol. 2002 Nov;2(11):845-58. Review.

PMID:
12415308

Supplemental Content

Support Center